Home/Pipeline/ADG125

ADG125

Solid Tumors

PreclinicalPipeline Candidate

Key Facts

Indication

Solid Tumors

Phase

Preclinical

Status

Pipeline Candidate

Company

Adagene

About Adagene

Adagene is a China-based biotech focused on developing novel antibody therapeutics for cancer using its proprietary computational and AI-driven discovery platform. Its core technology, the Dynamic Precision Library (DPL), enables the generation of highly diverse and functional antibody candidates. The company has advanced multiple candidates into clinical trials and has established strategic partnerships with major pharmaceutical players. Its strategy centers on creating safer and more effective immuno-oncology treatments with improved therapeutic windows.

View full company profile

Therapeutic Areas

Oncology Immuno-Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
GSK4362676	GSK plc	Phase 1	Active
ABBV-154	AbbVie	Phase 1	Active
TAK-981	Takeda Pharmaceutical	Phase 1/2	Active
TAK-676	Takeda Pharmaceutical	Phase 1	Active
TAK-573	Takeda Pharmaceutical	Phase 1	Active
TAK-164	Takeda Pharmaceutical	Phase 1	Active
SHR-1316	Jiangsu Hengrui Medicine	Phase 1/2	Active
BAY 2927088	Bayer	Phase 1	Active
ASP1929	Astellas Pharma	Phase 2	Active
IBI188	Innovent Biologics	Phase 1	Active
Bispecific Antibody	Akeso	Phase 1/2	Active
CSPC-DM02	CSPC Pharmaceutical Group Limited	Phase 2	Active